Text Size

Dose Range Study of CD5789 in Acne Vulgaris

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Galderma
ClinicalTrials.gov Identifier:
NCT01616654
First received: June 8, 2012
Last updated: April 30, 2013
Last verified: April 2013
History of Changes
  Purpose

To assess the efficacy and safety of different concentrations of CD5789 cream in subjects with acne vulgaris for the purpose of dose identification.


Condition Intervention Phase
Acne Vulgaris
 Drug: CD5789 25 µg/g cream
Drug: CD5789 50 µg/g cream
Drug: CD5789 100 µg/g cream
Drug: Tazarotene 0.1% gel
Drug: Vehicle cream
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris

Resource links provided by NLM:

MedlinePlus related topics: Acne
Drug Information available for: Tazarotene
U.S. FDA Resources

Further study details as provided by Galderma:

Primary Outcome Measures:
  • Success Rate (IGA) [ Time Frame: up to Week 12 ] [ Designated as safety issue: No ]
    Defined as the percentage of subjects who achieve at least a two-point reduction in the IGA score from Baseline at Week 12, Last Observation Carried Forward (LOCF), Intent to Treat (ITT) population.

  • Absolute change in total lesion counts [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
    Absolute change in total lesion counts from Baseline to Week 12; total lesion counts is the sum of inflammatory, non-inflammatory lesions and nodules.

  • Percent Change in total lesion counts [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
    Percent change in total lesion counts from Baseline to Week 12; total lesion counts is the sum of inflammatory, non-inflammatory lesions and nodules


Estimated Enrollment: 328
Study Start Date: June 2012
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CD5789 50 µg/g cream
CD5789 50 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
 Drug: CD5789 50 µg/g cream
CD5789 50 µg/g cream applied once daily
Experimental: CD5789 100 µg/g cream
CD5789 100 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
 Drug: CD5789 100 µg/g cream
CD5789 100 µg/g cream applied once daily
Active Comparator: Tazarotene 0.1% gel
Tazarotene 0.1% gel applied once daily for subjects randomized in Stratum 1 and 2
 Drug: Tazarotene 0.1% gel
Tazarotene 0.1% gel applied once daily
Placebo Comparator: Vehicle cream
Vehicle cream applied once daily for subjects randomized in Stratum 1, 2 and 3
 Drug: Vehicle cream
Vehicle cream applied once daily
Experimental: CD5789 25 µg/g cream
CD5789 25 µg/g cream applied once daily for subjects randomized in Stratum 1, 2 and 3
 Drug: CD5789 25 µg/g cream
CD5789 25 µg/g cream applied once daily

  Eligibility

Ages Eligible for Study:   12 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject, 12 to 35 years old with the following characteristics:

  • Facial acne severity grade of the following:

    • Stratum 1: IGA score of 3 or 4
    • Stratum 2: IGA score of 4
    • Stratum 3: IGA score of 3 or 4

  • A minimum of 30 non-inflammatory lesions and fulfills the criteria of one of the following strata:

    • Stratum 1: A minimum of 20 but not more than 40 inflammatory lesions, and a maximum of one nodule on the face.
    • Stratum 2: More than 40 inflammatory lesions, and up to four nodules on the face.

    • Stratum 3: Subjects of Japanese origin with at least 20 inflammatory lesions and up to four nodules on the face.

      • Note: Subjects of Japanese origin will not be included in Stratum 1 or Stratum 2. Japanese origin is defined as all four grandparents were born in Japan.

Exclusion Criteria:

  • The presence of severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)
  • Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject participates in the clinical trial.
  • Known or suspected allergies or sensitivities to any components of any of the study drugs.
  • Current participation in any other clinical trial of a drug or device OR past participation within the 30 days prior to the Baseline visit.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01616654

  Show 24 Study Locations
Sponsors and Collaborators
Galderma
Investigators
Study Director: Michael Graeber, M.D. Galderma R&D, Inc.
  More Information

No publications provided

Responsible Party: Galderma
ClinicalTrials.gov Identifier: NCT01616654     History of Changes
Other Study ID Numbers: RD.06.SPR18223
Study First Received: June 8, 2012
Last Updated: April 30, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Tazarotene
Nicotinic Acids
Keratolytic Agents
 Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013